Victor Pimentel-Quiroz

👨‍🔬 Rheumatologist in Hospital Nacional Guillermo Almenara Irigoyen - Peru
📌 Interested in Vasculitis, IgG4-RD, SLE
🩻 Head of the Almenara Vasculitis Cohort

[Victor Pimentel-Quiroz @VictorioPQ]

👇👇👇👇👇👇👇👇👇👇👇👇

[Maine-Anjou AAV-GN Research Group @MaineAnjouReg]

What do we know about prognostic kidney lesions in #ANCA #vasculitis ? A thread. 🧵1/x

[Manuel Ugarte-Gil @mugartegil]

It has been an intense and very productive week in London, with the #SLICC meeting and the #EULAR2026. During the #EULAR2026 I presented two posters on #sustained #drug-free #remission in the #SLICC cohort, and also one abstract led by @VictorioPQ with the @gladel_latam cohort

[Jiha Lee @JihaRheum]

#EULAR2026 Recommendations: Vasculitis

-Confirm diagnosis with imaging and biopsy
- Start GC early but with taper plan
- For major flare again confirm dx and restart GC
- Consider IL-6 or UPA
- MTX may be option if biologics not available

@RheumNow

[Antoni Chan MD (Prof) @synovialjoints]

Abstr LB0009

Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up.

VTE: HR 1.61 (95% CI 0.97–2.66)
non-inferiority not demonstrated

MACE: HR 1.06 no cardiovascular excess

Serious infections: HR 1.32 (p<0.05)

@RheumNow #EULAR2026

[Roxana González @RoxOsler]

POS0990: What drives mortality in AAV today? In this nationwide cohort, excess mortality was mainly driven by infections, kidney disease and vasculitis itself. Infection-related mortality was particularly pronounced during the first year after diagnosis. #EULAR2026

[Dr. John Cush @RheumNow]

TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) &amp; mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190

[Janet Pope @Janetbirdope]

Data of #Rituximab
In #SARD-ILD
Small N of #RA-#ILD pts

I think data are sufficient as #RWE of #RTX in RA-ILD
✅benefits in other #CTD ILD
✅benefits in #rheumatoid #arthritis

#EVER-ILD #RCT

HOT #RA-ILD topic June 5
#EULAR2026
@RheumNow

[Antoni Chan MD (Prof) @synovialjoints]

Phase 3 RCT. 46 patients with early PMR (≤3 weeks from diagnosis). Baricitinib 4mg + rapid steroid taper vs placebo + steroid taper for 16 weeks.

GC-free remission at Week 16:
65% baricitinib vs 17% placebo (p=0.002)

Nearly 4× the steroid-free remission rate. Cumulative steroid dose at Week 16: 962mg (baricitinib) vs 1,183mg (placebo), p=0.007

LB0005 @RheumNow #EULAR2026

[Manuel Ugarte-Gil @mugartegil]

This an abstract from @VictorioPQ from @gladel_latam about the efficacy of #MMF and #cyclophosphamide in #lupus #nephritis #EULAR2026 @GEAS_Peru

[Rheumatology update @aabdogafar]

EULAR 2026 JAK Inhibition in Large Vessel Vasculitis

[Manuel Ugarte-Gil @mugartegil]

If you are at the #EULAR26 come and visit us at the poster session! Predictors of sustained drug-free #remission in #SLE #SLICC @geas_peru

[Roxana González @RoxOsler]

SELECT-GCA extension focused on UPA 15 mg in GCA through 2 years ➡️ From weeks 52–104, continuous UPA benefited both new-onset and relapsing GCA, while switch to placebo was associated with more flares, lower remission and higher cumulative GC exposure. #EULAR2026 #vasculitis

[NEJM @NEJM]

Presented at #EULAR2026:

Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission than a glucocorticoid taper alone. Full phase 3 REPLENISH trial results: https://t.co/w1oD5ug1kJ

Editorial: Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting https://t.co/I13JtK01EA

Original Article in @NEJMEvidence: Secukinumab for Giant Cell Arteritis (phase 3 GCAptAIN trial) https://t.co/0dWjwDaEHs

@eular_org

[NEJM @NEJM]

Presented at #EULAR2026:

In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: https://t.co/Lynf6nmA9N

Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease https://t.co/BUQ7r8jVWz

@eular_org

[RMD Open @bmj_rmdopen]

🧬 HA20 is not a single phenotype.

In 17 patients from 6 families with TNFAIP3 variants:
✅ Oral aphthosis: 88%
✅ Recurrent fever: 53%
✅ GI inflammation: 53%
✅ Autoimmunity: 47%
✅ Neuropsychiatric symptoms: 41%

Early onset before age 5 was linked to more neuropsychiatric involvement, while arthritis appeared more often with later onset.
Type 1 IFN signature may help monitor disease activity.

🔓 https://t.co/GSJeBBwGpo

[ANCA Vasculitis News @AncaVasculitis]

Hispanic children with AAV are more likely to have severe disease and to develop kidney failure than white children, according to a study. https://t.co/br5Jk7rw7Y

[ACR_Journals @ACR_Journals]

A 19-year-old man presented with persistent anterior chest pain. Lab tests showed elevated ESR of 30 mm/h & high-sensitivity CRP level of 11.2 mg/L. HLA-B51, HLA-B27, ANA, ANCA, RF, and anti–CCP antibody tests were all negative. PET-CT scan demonstrated increased FDG uptake at the bilateral costochondral junctions (A)

Clinical images in ACR Open Rheumatology
https://t.co/8DkPCmGUFN

[The Lancet Rheumatology @TheLancetRheum]

NEW RESEARCH—Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study https://t.co/4oMMNcaPEw

[RMD Open @bmj_rmdopen]

VEDOSS vs pre-#SystemicSclerosis: boundaries remain blurred.

This scoping review found major variability in how very early diagnosis of systemic sclerosis and pre-SSc are defined.

✅ 40 original articles included
✅ 3 definitions of pre-SSc identified
✅ 13 different applications of VEDOSS criteria
✅ Only 31.3% applied the complete VEDOSS definition
✅ Some studies included patients with visceral or fibrotic complications, challenging the “very early” concept

A consensus definition of pre-SSc is needed to support risk stratification and future preventive trials.

🔓 https://t.co/uhQofaGNv9

[JCR: Journal of Clinical Rheumatology @JRheumatology]

👁️⚡ Fast-track clinics in Giant Cell Arteritis
348 patients 1:1
FTC decreased permanent sight loss (8.09% vs. 24.57%, OR: 0.31; p&lt;0.001) and visual disturbances (20.23% vs. 32.57%, OR: 0.58; p=0.04) compared with CP.
Early diagnosis saves vision! https://t.co/l44DJM5NVi